Preferencje help
Polish version English version Język
Widoczny [Schowaj] Abstrakt
Liczba wyników

Znaleziono wyników: 8

Liczba wyników na stronie
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników

Wyniki wyszukiwania

help Sortuj według:

help Ogranicz wyniki do:
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników
1

Microsatellite instability at RAD51 locus in breast cancer

100%
Nowacka M., Brys M., Romanowicz-Makowska H., Krajewska W.
Acta Biochimica Polonica
|
2003
|
tom 50
|
nr Supplement 1
2

Etanol i aldehyd octowy: udzial w procesach mutagenezy i karcynogenezy

100%
Trzeciak A., Malecka-Panas E., Romanowicz-Makowska H., Kulig A.
Postępy Biologii Komórki
|
2001
|
tom 28
|
nr 4
543-559
3

Plasminogen activator inhibitor 1 [PAI-1] 1334G-A genetic polymorphism in colorectal cancer

100%
Smolarz B., Romanowicz-Makowska H., Kulig A.
Acta Biochimica Polonica
|
2003
|
tom 50
|
nr 2
Plasminogen activator inhibitor 1 (PAI-1) content in colorectal cancer tissue ex­tracts may be of strong prognostic value: high levels of PAI-1 in tumours predict poor prognosis. The gene encoding PAI-1 is highly polymorphic and PAI-1 gene variability could contribute to the level of PAI-1 biosynthesis. In the present work the distribu­tion of genotypes and frequency of alleles of the 1334G/A polymorphism in 92 subjects with colorectal cancer in samples of cancer tissue and distant mucosa samples as well as in blood were investigated. Blood samples age matched healthy individuals (n = 110) served as control. The 1334G/A polymorphism was determined by PCR ampli­fication using allele specific primers. No differences in the genotype distributions and allele frequencies between blood, distant mucosa samples and cancer tissue were de­tected. However, the distribution of the genotypes of the 1334G/A polymorphism in patients differed significantly (P < 0.05) from those predicted by the Hardy-Weinberg equilibrium. There were significant differences in the frequencies of alleles between the colorectal cancer subjects and controls (P < 0.05). The results support the hypothe­sis that the 1334G/A polymorphism may be associated with the incidence of colorectal cancer.
4

Genomic instability in the RAD51 and BRCA2 regions in breast cancer

88%
Nowacka-Zawisza M., Brys M., Romanowicz-Makowska H., Kulig A., Krajewska M.
Acta Biochimica Polonica
|
2006
|
tom 53
|
nr Supplement 1
5

Genetic instability in the RAD51 and BRCA1 regions in breast cancer

88%
Nowacka-Zawisza M., Brys M., Romanowicz-Makowska H., Kulig A., Krajewska W. M.
Cellular and Molecular Biology Letters
|
2007
|
tom 12
|
nr 2
Breast cancer is the most prevalent cancer type in women. Accumulating evidence indicates that the fidelity of double-strand break repair in response to DNA damage is an important step in mammary neoplasias. The RAD51 and BRCA1 proteins are involved in the repair of double-strand DNA breaks by homologous recombination. In this study, we evaluated loss of heterozygosity (LOH) in the RAD51 and BRCA1 regions, and their association with breast cancer. The polymorphic markers D15S118, D15S214 and D15S1006 were the focus for RAD51, and D17S855 and D17S1323 for BRCA1. Genomic deletion detected by allelic loss varied according to the regions tested, and ranged from 29 to 46% of informative cases for the RAD51 region and from 38 to 42% of informative cases for the BRCA1 region. 25% of breast cancer cases displayed LOH for at least one studied marker in the RAD51 region exclusively. On the other hand, 31% of breast cancer cases manifested LOH for at least one microsatellite marker concomitantly in the RAD51 and BRCA1 regions. LOH in the RAD51 region, similarly as in the BRCA1 region, appeared to correlate with steroid receptor status. The obtained results indicate that alteration in the RAD51 region may contribute to the disturbances of DNA repair involving RAD51 and BRCA1 and thus enhance the risk of breast cancer development.
6

Expression of the TGF-beta receptors and Smad proteins in human endometrial cancers

76%
Piestrzeniewicz D., Semczuk A., Brys M., Romanowicz-Makowska H., Jakowicki J. A., Krajewska W. M.
Cellular and Molecular Biology Letters
|
2000
|
tom 05
|
nr 2
7
Content available remote

Vascular endothelial growth factor (VEGF) genotype and serum concentration in patients with pancreatic adenocarcinoma and chronic pancreatitis

64%
Talar-Wojnarowska R., Gasiorowska A., Olakowski M., Lekstan A., Lampe P., Smolarz B., Romanowicz-Makowska H., Kulig A., Malecka-Panas E.
Journal of Physiology and Pharmacology
|
2010
|
tom 61
|
nr 6
8
Content available remote

Usufulness of p16 and K-ras mutation in pancreatic adenocarcinoma and chronic pancreatitis differential diagnosis

64%
Talar-Wojnarowska R., Gasiorowska A., Smolarz B., Romanowicz-Makowska H., Strzelczyk J., Janiak A., Kulig A., Malecka-Panas E.
Journal of Physiology and Pharmacology. Supplement
|
2004
|
tom 55
|
nr 2
129-138
The differentiation of chronic pancreatitis (CP) from pancreatic adenocarcinoma (PA) remains a great challenge. The purpose of the study was to compare the prevalence of p16 and K-ras mutation in PA and CP in order to evaluate their usefulness in differential diagnosis of those diseases. Methods: The study included 44 patients who underwent Whipple resection or distal pancreatectomy for PA (23 subjects) or CP (21 subjects). DNA from pancreatic tissue was analysed for K-ras mutation (codon 12) and p16 mutations with PCR amplifications. Results: The K-ras gene mutation has been shown in 17 (73,9%) cases with pancreatic adenocarcinoma which was significantly more often than in chronic pancreatitis - 9 (42,8%) (p<0,01). Prevalence of p16 mutations in patients with PA was 18 (78,3%) and with CP - 7 (33,3%) (p<0,01). K-ras and p16 mutations together have been observed in 16 (69,6%) cases in patients with PC and only in 3 (14,3%) - with CP (p<0,01). No statistically significant association between K-ras or p16 mutations and tumor size, sex or patient age has been observed. Conclusion: It is suggested that simultaneous measurement of K-ras and p16 mutations may provide an additional tool in differential diagnosis of chronic pancreatitis and pancreatic adenocarcinoma.
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.